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ABSTRACT
Acinetobacter baumannii and Acinetobacter DNA group 3 are members of the so-called A. calcoaceticus–
A. baumannii complex and are important nosocomial pathogens. Multiresistance in these organisms is
increasingly frequent, and alternative treatment options are needed. The b-lactamase inhibitors
clavulanate, sulbactam and tazobactam have intrinsic activity against Acinetobacter strains. In the present
study, broth microdilution was used to assess the in-vitro activities of currently available b-lactam ⁄
b-lactamase inhibitor combinations and sulbactam alone against 469 Acinetobacter isolates (A. baumannii,
n = 395; Acinetobacter DNA group 3, n = 74) collected from various laboratories in Germany. Fixed
concentrations and ﬁxed ratios of b-lactamase inhibitors were used. Sulbactam-containing combinations
(susceptibility rates of 90.4–92.7% for A. baumannii and 97.3–100% for Acinetobacter DNA group 3) and
sulbactam alone were superior to clavulanate- and tazobactam-containing combinations. The activity of
sulbactam-containing combinations against members of the A. calcoaceticus–A. baumannii complex was
conferred exclusively by the intrinsic activity of the b-lactamase inhibitor and did not result from
enhanced b-lactam activity. Testing with the inhibitor added at a ﬁxed ratio of inhibitor to b-lactam
appeared to give more reliable results than testing at a ﬁxed concentration of the inhibitor. Resistance to
carbapenems (0.3%) remains low in Germany.
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INTRODUCTION
Acinetobacter species have received increasing
attention during the past two decades as signiﬁ-
cant opportunistic pathogens, usually in the
context of serious underlying disease [1–3].
Nosocomial infections and hospital outbreaks
have been attributed mainly to Acinetobacter bau-
mannii, although other members of the so-called
A. calcoaceticus–A. baumannii complex, such as
Acinetobacter DNA groups 3 and 13 sensu
Tjernberg and Ursing, have also been implicated
in nosocomial infections [4–6]. Multiresistance is
common among these organisms and leaves few
therapeutic options. Even resistance to the carb-
apenems, which are commonly regarded as the
drugs of choice for Acinetobacter infections, has
become increasingly common in various parts of
the world [7–11], and alternative treatment strat-
egies are needed urgently.
The b-lactamase inhibitors clavulanate, sulbac-
tam and tazobactam have intrinsic antibacterial
activity against Acinetobacter strains at concen-
trations readily achievable in man [12–17].
Ampicillin–sulbactam combinations and sulbac-
tam alone have both been used successfully in
animal models [18] and for the treatment of
serious nosocomial infections in man caused by
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multiresistant A. baumannii [19,20]. There are
differences in currently available antimicrobial
susceptibility testing guidelines regarding the
precise inhibitor concentration to use when
testing b-lactam ⁄ b-lactamase inhibitor combina-
tions. The NCCLS guidelines for testing
susceptibility to amoxycillin–clavulanate and
ampicillin–sulbactam specify an inhibitor ⁄
b-lactam ratio of 2:1 [21,22], while the German
guidelines and those of the Antibiogram Com-
mittee of the French Society for Microbiology
specify ﬁxed concentrations of clavulanate
2 mg ⁄L and sulbactam 8 mg ⁄L, respectively
[23–25], and the British Society for Antimicrobial
Chemotherapy guidelines do not contain any
recommendation [26]. For piperacillin–tazobac-
tam, all four guidelines require a ﬁxed inhibitor
concentration of 4 mg ⁄L. Interestingly, for ticar-
cillin–clavulanate, the NCCLS guidelines require
that the inhibitor should be tested at a ﬁxed
concentration of 2 mg ⁄L.
The present study was conducted in order to
assess the in-vitro activity of currently available
b-lactam ⁄b-lactamase inhibitor combinations and
sulbactam alone against 469 clinically signiﬁ-
cantly isolates belonging to the A. calcoaceticus–
A. baumannii complex that were collected from
various laboratories in Germany. Both ﬁxed con-
centrations and ﬁxed ratios of inhibitors were
tested.
MATERIALS AND METHODS
Bacterial isolates
Thirteen microbiology laboratories from various hospitals
located throughout Germany were asked to provide recent
non-replicate isolates of Acinetobacter spp., obtained preferably
from patients in intensive care units or from blood cultures. In
addition, the laboratories at the Universities of Cologne, Frei-
burg and Leipzig each contributed 100 recently collected non-
replicate Acinetobacter isolates from routine clinical specimens.
All isolates were identiﬁed provisionally as Acinetobacter
spp. with the routine methods in use at the participating
laboratories, including Gram’s stain morphology, motility
testing, negative oxidation ⁄ fermentation and oxidase tests, as
well as commercial identiﬁcation systems. After susceptibility
testing had been performed at the laboratories in Bonn,
Cologne, Freiburg and Leipzig (see below), isolates were sent
to the central laboratory at the Institute for Medical Microbio-
logy, Immunology and Hygiene at the University of Cologne
for further investigation. Identiﬁcation of Acinetobacter spp. to
the genus level was conﬁrmed with the transformation assay
described by Juni [27]. Isolates belonging to the A. calcoacet-
icus–A. baumannii complex were identiﬁed phenotypically with
the temperature growth assay of Bouvet and Grimont [28],
including growth in tryptic soy broth at 37C, 41C and 44C.
Isolates growing at 44C were identiﬁed presumptively as
A. baumannii. Isolates growing at 41C but not at 44C were
subjected to ampliﬁed ribosomal DNA restriction analysis for
species identiﬁcation [29]. Isolates not identiﬁed as either
A. baumannii or Acinetobacter DNA group 3 were excluded
from the ﬁnal analysis.
Susceptibility testing
MICs were determined by NCCLS reference broth microdilu-
tion methods in cation-adjusted Mueller–Hinton broth (Oxoid,
Wesel, Germany) with a ﬁnal inoculum of 5 · 105 CFU ⁄mL
[21]. Fixed concentrations of inhibitor and ﬁxed inhibitor ⁄
b-lactam ratios were both tested [22–26]. Microtitre plates
containing dehydrated antibacterial agents were obtained
from Merlin Diagnostica (Bornheim-Hersel, Germany). The
antibacterial agents and concentration ranges tested, in
two-fold steps, were: amoxycillin–clavulanate 0.06 ⁄ 2–128 ⁄
2 mg ⁄L and 0.06 ⁄ 0.016–128 ⁄ 32 mg ⁄L; ampicillin–sulbactam
0.06 ⁄ 8–128 ⁄ 8 mg ⁄L and 0.06 ⁄ 0.03 mg ⁄L–128 ⁄ 64 mg ⁄L; mezlo-
cillin–sulbactam 0.06 ⁄ 0.016–128 ⁄ 32 mg ⁄L; piperacillin 0.06–
128 mg ⁄L; piperacillin–sulbactam 0.06 ⁄ 8–128 ⁄ 8 mg ⁄L and
0.06 ⁄ 0.016–128 ⁄ 32 mg ⁄L; piperacillin–tazobactam 0.06 ⁄ 4-
128 ⁄ 4 mg ⁄L and 0.06 ⁄ 0.008–128 ⁄ 16 mg ⁄L; cefotaxime 0.06–
128 mg ⁄L; cefotaxime–sulbactam 0.06 ⁄ 0.03 to 64 ⁄ 32 mg ⁄L;
meropenem 0.06–128 mg ⁄L; ciproﬂoxacin 0.06–128 mg ⁄L;
and sulbactam 0.06–128 mg ⁄L as a single agent. The panels
were incubated in ambient air at 35C for 16–20 h. Trays were
read manually, and an endpoint of no organism growth was
recorded as the MIC according to NCCLS standards [21].
Susceptibility rates were determined according to NCCLS
breakpoints [22]. If these were not available for certain
b-lactam ⁄b-lactamase inhibitor combinations, the breakpoint
for the respective b-lactam alone was used. Quality control
was performed with the following strains recommended by
the NCCLS: Staphylococcus aureus ATCC 29213, Enterococcus
faecalis ATCC 29212, Escherichia coli ATCC 25922 and ATCC
35218, and Pseudomonas aeruginosa ATCC 27853 [21].
RESULTS
Bacterial isolates
From an initial total of 505 presumptive Acineto-
bacter isolates, eight were excluded as not
belonging to the genus Acinetobacter, and a
further 28 were identiﬁed as Acinetobacter spp.
that did not belong to the A. calcoaceticus–
A. baumannii complex. The remaining 469 isolates
were identiﬁed as A. baumannii (n = 395; 84.2%)
and Acinetobacter DNA group 3 (n = 74; 15.8%).
Most (75%) specimens submitted for microbio-
logical investigation were obtained from inten-
sive care unit patients. The main types of clinical
specimens included blood cultures (36.4%), low-
er respiratory tract specimens (34.3%), urine
(7%) and upper respiratory tract specimens
(4.7%).
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Susceptibilities
The in-vitro activities of the various compounds
against A. baumannii and Acinetobacter DNA
group 3 are presented in Tables 1 and 2. Ampi-
cillin–sulbactam and piperacillin–sulbactam (with
the inhibitor added at a ﬁxed concentration of
8 mg ⁄L) and meropenem showed the highest
activities against A. baumannii, with MIC90 values
of £ 0.06, £ 0.06 and 1 mg ⁄L, respectively. Moder-
ate activity (MIC90 values ranging between 8 and
32 mg ⁄L) was observed for: ampicillin–sulbactam
(2:1) 8 mg ⁄L; cefotaxime–sulbactam (2:1) 8 mg ⁄L;
mezlocillin–sulbactam (4:1) 16 mg ⁄L; piperacil-
lin–sulbactam (4:1) 16 mg ⁄L; ciproﬂoxacin,
32 mg ⁄L; and sulbactam alone 8 mg ⁄L. A similar
level of activity and a similar MIC distribution
were found when sulbactam was tested alone or
in combination with ampicillin, mezlocillin or
piperacillin at a ﬁxed ratio, reﬂecting the intrinsic
activity of the inhibitor.
Low activity (MIC90 ‡ 64 mg ⁄L) was observed
with the two amoxycillin–clavulanate combina-
tions, piperacillin, piperacillin–tazobactam (8:1)
and cefotaxime. Many isolates did not have a
readable MIC for piperacillin–tazobactam with
the ﬁxed inhibitor concentration of 4 mg ⁄L
because of trailing; i.e., slight-to-moderate growth
occurred at a number of concentrations, and no
clear endpoint was reached; MIC50 and MIC90
determination was therefore not considered to be
possible.
In contrast to the MIC values, susceptibility
rates with b-lactam ⁄ b-lactamase inhibitor combi-
nations were not affected by whether the inhibitor
was added at a ﬁxed ratio or at a ﬁxed concen-
tration. b-Lactam ⁄b-lactamase inhibitor combina-
tions containing sulbactam were associated with
susceptibility rates of 90–92%, in contrast to am-
oxycillin–clavulanate combinations,whichyielded
a susceptibility rate of 33–34%. The susceptibility
rates with the other compounds were (in rank
order) as follows:meropenem, 98.7%; piperacillin–
tazobactam (8:1), 79.7%; ciproﬂoxacin, 78.2%;
piperacillin, 68.6%; and cefotaxime, 48.4%
(Table 1).
With Acinetobacter DNA group 3, the highest
activity was also observed for ampicillin–
Table 1. MIC distributions of various b-lactams, b-lactam ⁄ b-lactamase inhibitor combinations and other antimicrobial
agents determined with broth microdilution for 395 Acinetobacter baumannii isolates
Antimicrobial agent
Number of isolates with MIC (mg ⁄L) Susceptiblec
£ 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 ‡ 256 MIC50 MIC90 Range n %
Amoxycillin–
clavulanate (2 mg)a
7 1 2 4 5 15 40 64 110 76 15 18 38 16 128 £ 0.06–‡ 256 (138) (34.9)
Amoxycillin–
clavulanate (2:1)b
0 0 0 5 4 12 46 67 120 78 25 24 14 16 64 0.5–‡ 256 134 33.9
Sulbactam 0 0 17 94 135 90 19 8 20 6 3 3 0 1 8 0.25–128 ND ND
Ampicillin–
sulbactam (8 mg)a
364 1 0 0 0 0 0 1 0 1 1 14 13 £ 0.06 £ 0.06 £ 0.06–‡ 256 (366) (92.7)
Ampicillin–
sulbactam (2:1)b
0 0 2 15 108 159 58 17 6 14 11 5 0 2 8 0.25–128 359 90.9
Cefotaxime 0 0 1 3 4 17 64 102 119 29 13 30 13 16 128 0.25–‡ 256 191 48.4
Cefotaxime–
sulbactam (2:1)b
0 1 7 55 108 127 50 18 6 18 5 0 0 2 8 0.125–64 (366) (92.7)
Mezlocillin–
sulbactam (4:1)b
0 0 0 4 30 127 128 52 16 13 16 9 0 4 16 0.5–128 (357) (90.4)
Piperacillin 0 0 0 0 1 10 26 105 129 47 14 36 27 16 128 1–‡ 256 271 68.6
Piperacillin–
sulbactam (8 mg)a
363 1 0 0 0 1 0 0 0 2 1 19 8 < 0.06 < 0.06 < 0.06–‡ 256 (364) (92.1)
Piperacillin–
sulbactam (4:1)b
1 1 0 4 38 137 118 45 17 6 17 10 1 4 16 < 0.06–‡ 256 (361) (91.4)
Piperacillin–
tazobactam (4 mg)a
ND ND < 0.06–‡ 256 ND ND
Piperacillin–
tazobactam (8:1)b
0 0 0 1 6 15 75 137 81 37 27 8 8 8 64 0.5–‡ 256 (315) (79.7)
Meropenem 38 76 114 93 54 13 2 4 1 0 0 0 0 0.25 1 £ 0.06–16 390 98.7
Ciproﬂoxacin 7 75 149 62 16 12 11 8 6 13 28 5 3 0.25 32 < 0.06–‡ 256 309 78.2
MIC50 and MIC90, MICs (mg ⁄L) for 50% and 90% of isolates tested, respectively. Bold type indicates NCCLS breakpoints applied for susceptible isolates for both b-lactams
alone and their various inhibitor combinations as well as other compounds: amoxycillin, ampicillin and cefotaxime 8 mg ⁄L; mezlocillin and piperacillin 16 mg ⁄L; meropenem
4 mg ⁄L; and ciproﬂoxacin 1 mg ⁄L.
aFixed concentration of b-lactamase inhibitor.
bFixed b-lactam ⁄ inhibitor ratio: 2:1, 4:1 and 8:1, respectively.
cNumber and percentage of susceptible isolates. If no breakpoint was available for a speciﬁc b-lactam–inhibitor combination, the breakpoint of the respective b-lactam alone
was applied (numbers in parentheses).
ND, not determined.
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sulbactam and piperacillin–sulbactam with the
inhibitor added at a ﬁxed concentration (MIC90
£ 0.06 mg ⁄L), and meropenem (MIC90 1 mg ⁄L).
In comparison with A. baumannii, the b-lactam ⁄
b-lactamase inhibitor combinations were slightly
more active against Acinetobacter DNA group 3
isolates when tested with a ﬁxed inhibitor ⁄ b-
lactam ratio, as well as sulbactam alone, i.e.,
ampicillin–sulbactam (2:1) MIC90 4 mg ⁄L; cefo-
taxime–sulbactam (2:1) 4 mg ⁄L; mezlocillin–sul-
bactam (4:1) 8 mg ⁄L; piperacillin–sulbactam (4:1)
8 mg ⁄L; and sulbactam 2 mg ⁄L. Lower activity
was observed for the other antibacterial agents,
with MIC90s as follows: piperacillin–tazobactam
(8:1) 32 mg ⁄L; amoxycillin–clavulanate (2:1)
32 mg ⁄L; amoxycillin–clavulanate (2 mg) 32 mg ⁄L;
piperacillin 32 mg ⁄L; cefotaxime 32 mg ⁄L; and
ciproﬂoxacin 32 mg ⁄L. Susceptibility rates are
listed in Table 2.
DISCUSSION
The present study with a large number of
A. baumannii isolates, recovered from various
major centres throughout Germany, is the largest
in-vitro study of Acinetobacter isolates reported
to date. Whereas previous studies have focused
primarily on isolates from strain collections, the
multicentre design of the present study, with use
of contemporary clinical isolates, allowed the
current epidemiological situation in Germany to
be assessed. The ﬁndings conﬁrmed the observa-
tions from previous studies that carbapenems
remain the most active agents, and that resistance
to this class of compounds is still very low in
Germany, with only one (0.3%) isolate being
resistant to meropenem. This contrasts with the
situation in other countries, such as Spain [7],
France [9], Brazil [10] and the USA [8], where
increasing carbapenem resistance is a cause for
concern and results in severely limited options for
antimicrobial therapy, such as colistin [30] and
sulbactam [31]. Carbapenems have been used
extensively in Germany over the past decade, and
we have no explanation for this strikingly low
resistance rate.
It has been shown previously that b-lactamase
inhibitors, in particular sulbactam, have intrinsic
Table 2. MIC distributions of various b-lactams, b-lactam ⁄ b-lactamase inhibitor combinations and other antimicrobial
agents determined with broth microdilution for 74 Acinetobacter DNA group 3 isolates
Antimicrobial agent
Number of isolates with MIC (mg ⁄L) Susceptiblec
£ 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 ‡ 256 MIC50 MIC90 Range n %
Amoxycillin–
clavulanate (2 mg)a
1 0 0 0 0 2 3 10 25 29 4 0 0 16 32 £ 0.06–64 (16) (21.6)
Amoxycillin–
clavulanate (2:1)b
0 0 0 0 1 1 3 11 29 26 3 0 0 16 32 1–64 16 21.6
Sulbactam 0 0 2 15 34 18 4 1 0 0 0 0 0 1 2 0.25–8 ND ND
Ampicillin–
sulbactam (8 mg)a
74 0 0 0 0 0 0 0 0 0 0 0 0 £ 0.06 £ 0.06 £ 0.06–£ 0.06 (74) (100)
Ampicillin–
sulbactam (2:1)b
0 0 0 3 12 41 12 4 2 0 0 0 0 2 4 0.5–16 72 97.3
Cefotaxime 0 0 1 0 1 2 11 21 26 9 2 1 0 16 32 0.25–128 36 48.6
Cefotaxime–
sulbactam (2:1)b
0 1 2 7 19 37 7 0 0 1 0 0 0 2 4 0.125–32 (73) (98.6)
Mezlocillin–
sulbactam (4:1)b
0 0 1 1 3 20 39 9 0 0 1 0 0 4 8 0.25–64 (73) (98.6)
Piperacillin 0 0 0 0 0 0 4 15 26 23 4 1 1 16 32 4–‡ 256 45 60.8
Piperacillin–
sulbactam (8 mg)a
72 0 0 1 0 0 0 0 0 0 0 1 0 £ 0.06 £ 0.06 £ 0.06–128 (73) (98.6)
Piperacillin–
sulbactam (4:1)b
0 0 0 1 4 26 33 8 2 0 0 0 0 4 8 0.5–16 (74) (100)
Piperacillin–
tazobactam (4 mg)a
ND ND £ 0.06–128 ND ND
Piperacillin–
tazobactam (8:1)b
0 0 0 1 0 1 8 25 30 7 2 0 0 16 32 0.5–64 (65) (87.8)
Meropenem 3 10 30 17 9 5 0 0 0 0 0 0 0 0.25 1 £ 0.06–2 74 100
Ciproﬂoxacin 0 13 28 10 2 3 2 4 3 7 2 0 0 0.25 32 0.125–64 53 71.6
MIC50 and MIC90, MICs (mg ⁄L) for 50% and 90% of isolates tested, respectively. Bold type indicates NCCLS breakpoints applied for susceptible isolates for both b-lactams
alone and their various inhibitor combinations as well as other compounds: amoxycillin, ampicillin and cefotaxime 8 mg ⁄L; mezlocillin and piperacillin 16 mg ⁄L; meropenem
4 mg ⁄L; and ciproﬂoxacin 1 mg ⁄L.
aFixed concentration of b-lactamase inhibitor.
bFixed b-lactam ⁄ inhibitor ratio: 2:1, 4:1 and 8:1, respectively.
cNumber and percentage of susceptible isolates. If no breakpoint was available for a speciﬁc b-lactam–inhibitor combination, the breakpoint of the respective b-lactam alone
was applied (numbers in parentheses).
ND, not determined.
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activity against A. baumannii [10,12–15]. However,
clinical experience with b-lactam ⁄b-lactamase
inhibitor combinations used for the treatment of
serious nosocomial infections caused by
A. baumannii is limited almost exclusively to
ampicillin–sulbactam, which has been shown to
be efﬁcacious in the treatment of multiresistant
A. baumannii meningitis, ventilator-associated
pneumonia, and catheter-related bacteraemia
[19,20,31]. Since sulbactam is also available com-
mercially in Germany as a single agent, sulbactam
alone was tested against ampicillin–sulbactam
and various combinations of sulbactam and other
b-lactams, such as mezlocillin, piperacillin and
cefotaxime. In agreement with previous results
[13–15], of the various b-lactam ⁄b-lactamase
inhibitor combinations tested, sulbactam combi-
nations showed the highest activity against both
A. baumannii and Acinetobacter DNA group 3
isolates, with susceptibility rates exceeding 90%
for A. baumannii and 97% for Acinetobacter DNA
group 3. These susceptibility rates were signiﬁ-
cantly higher than those reported by Pandey et al.
[14] and Higgins et al. [15], and the MIC50s and
MIC90s were lower than those recorded by Visalli
et al. [13], perhaps reﬂecting differences in strain
selection. The present data show clearly that
sulbactam-containing b-lactam combinations
exert their activity against A. baumannii and
Acinetobacter DNA group 3 isolates exclusively
through their sulbactam component. Thus, with
the inhibitor added to the b-lactam at a ﬁxed ratio,
i.e., sulbactam alone > ampicillin–sulbactam
(2:1) > mezlocillin–sulbactam (4:1) = piperacil-
lin–sulbactam (4:1), as the sulbactam concentra-
tion decreased by one log2 step for any given
antimicrobial concentration, not only the MIC50s
and MIC90s, but also the MIC values for any given
strain, rose accordingly, and a parallel shift in the
MIC distribution by one or two log2 dilutions,
respectively, was observed. However, if sulbac-
tam was added at a ﬁxed concentration of 8 mg ⁄L
to ampicillin and piperacillin, as recommended in
the German and French guidelines [24,25], most
A. baumannii isolates (n = 363; 92%) had an MIC
of £ 0.06 mg ⁄L for the combination. This results
from the fact that exactly 363 A. baumannii isolates
had a sulbactam MIC of £ 8 mg ⁄L. Misleadingly,
this suggests extremely high activity of the drug
combination against these multiresistant strains,
with MICs at least ﬁve dilution steps lower than if
testing was done with a ﬁxed inhibitor ⁄ b-lactam
ratio, as proposed by the NCCLS [21,22]. Assu-
ming that concentrations of sulbactam following
parenteral administration range from 20 to
60 mg ⁄L for serum and from 2 to 16 mg ⁄L for
tissues [16], this may not have a major impact on
therapy for mild-to-moderate urinary tract, res-
piratory tract or bloodstream infections. How-
ever, in the case of deep-seated infections such as
meningitis, where drug levels in cerebrospinal
ﬂuid that greatly exceed the MIC are necessary for
cure [20], the therapeutic outcome may depend on
the actual sulbactam MIC, which can be deter-
mined accurately only if sulbactam is tested alone
or, following NCCLS guidelines, at a ﬁxed inhib-
itor ⁄ b-lactam ratio.
Clavulanate-containing combinations were less
active, and susceptibility rates were between 30%
and 35%. Since clavulanate and tazobactam MICs
for Acinetobacter isolates are considerably higher
than those of sulbactam [13], MIC values and
distribution are less affected by whether these
inhibitors are added at a ﬁxed concentration or a
ﬁxed ratio to the corresponding b-lactam. The
combination of tazobactam with piperacillin
resulted in only a moderate increase in the level
of sensitivity, from 68% to 79% if testing was
done at a ﬁxed ratio of 8:1. However, if testing
was done with the ﬁxed inhibitor concentration of
4 mg ⁄L, as recommended by various national
guidelines [21–26], a readable MIC against pip-
eracillin–tazobactam was not recordable for many
isolates,with slight-to-moderate growth (‘trailing’)
occurring in many tubes, making endpoint deter-
mination impossible. This probably results from
the fact that some A. baumannii isolates resistant to
piperacillin have tazobactam MICs of 4–16 mg ⁄L,
and are thus only inhibited partly by the tazo-
bactam component (4 mg ⁄L) of the piperacillin–
tazobactam combination [13]. In addition, as with
sulbactam, a large group of isolates—those with a
tazobactam MIC of £ 4 mg ⁄L—appeared to be
highly sensitive to piperacillin–tazobactam, with
MICs of £ 0.06 mg ⁄L (data not shown). Overesti-
mation of the activity of piperacillin–tazobactam
may result in an unfavourable clinical response,
especially in the case of deep-seated infections
with a large bacterial inoculum. Therefore, when
acinetobacters are being tested, the results of
sensitivity testing for piperacillin–tazobactam
with the inhibitor added at a ﬁxed concentration
should be interpreted with caution, or this test
should be avoided.
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In summary, the data from this study indicate
that the in-vitro results of susceptibility testing
for b-lactam ⁄ b-lactamase inhibitor combinations
against A. baumannii and Acinetobacter DNA
group 3 isolates depend on whether a ﬁxed
inhibitor ⁄ b-lactam ratio or a ﬁxed concentration
of the inhibitor is used. In the case of sulbactam-
containing combinations, the antimicrobial activ-
ity against isolates resistant to the b-lactam is
determined exclusively by the intrinsic activity of
sulbactam alone and does not result from
b-lactamase inhibition. Among currently available
b-lactamase inhibitors, sulbactam is the most
active agent against both A. baumannii and Acine-
tobacter DNA group 3 isolates, and this compound
may therefore be a therapeutic option for cases of
infection caused by multiresistant A. baumannii
and Acinetobacter DNA group 3 strains. The
results of antimicrobial susceptibility testing of
b-lactam ⁄b-lactamase inhibitor combinations,
particularly if the inhibitor is used at a ﬁxed
concentration, should be interpreted with caution.
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